This is in continuation to our letters dated September 22, 2025 & November 03, 2025 communicating closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015, ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sai Capital's board approved its Q2 and H1 FY26 results on November 14, 2025. On a standalone basis, the company reported zero revenue from operations, with a loss before tax of Rs 16.49 lakh in Q2 (vs Rs 17.46 lakh loss in Q2 FY25) and Rs 31.70 lakh loss in H1 FY26. Other equity is deeply negative at Rs (728.49) lakh, showing accumulated standalone losses. The consolidated picture is very different, driven by subsidiaries (Health Care Energy Foods, Unisphere Industries, Butterfly Ayurveda): total income surged to Rs 680.84 lakh in Q2 (up ~47% YoY) and Rs 1,280.42 lakh in H1 FY26, while profit after tax jumped to Rs 356.26 lakh in Q2 (up ~117% YoY) and Rs 667.56 lakh in H1 FY26. The statutory auditor (Mehrotra & Co) issued an unmodified limited review report on both sets of results.
Shareholders should note the sharp divergence between standalone (dormant, loss-making, negative net worth) and consolidated (strong profit growth) numbers – nearly all earnings come from subsidiaries. Consolidated PAT growth of over 100% YoY is a positive signal, but the very negative consolidated operating cash flow of about Rs (4,751) lakh in H1 FY26 warrants attention on cash quality of earnings.